MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin^®) in Relapsed Metastatic Colorectal Cancer Patients

MEI Pharma, Inc. reported that 25% of evaluable patients with relapsed metastatic colorectal cancer in Cohort 1 of the ongoing Phase Ib study evaluating ME-344, an investigational inhibitor of mitochondrial oxidative phosphorylation, in combination with bevacizumab had no disease progression at Week 16.